Global CAR-T Cell Therapy Market Size & Industry Report

Link

September 23, 2025 2:08 am

CAR-T Cell Therapy Market Share, Global Industry Size, Trends, Technology, and Analysis by 2035 CAR-T Cell Therapy Market Overview The CAR-T cell therapy market is likely to grow from USD 4.6 billio... View MoreCAR-T Cell Therapy Market Share, Global Industry Size, Trends, Technology, and Analysis by 2035 CAR-T Cell Therapy Market Overview The CAR-T cell therapy market is likely to grow from USD 4.6 billion in 2024 to reach USD 5.1 billion in 2025 and USD 15.2 billion by 2035, representing a CAGR of 11.4% during the forecast period. CAR-T cell therapy, amidst the active initiatives undertaken to develop more targeted anti-cancer therapies, CAR-T therapies have emerged as a promising option, given their ability to eradicate tumor cells from the body with minimal treatment-related side effects. Further, CAR T cell therapy, a relatively recent addition to the gamut of anticancer interventions, has demonstrated significant promise. Overall, this highly specific and promising form of CAR T therapy treatment, which harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment, globally. Key Report Takeaways With more than 800 therapy programs in the clinical phases of development, CAR-T cell therapies have already established a strong foothold in the overall pharmaceutical industry. Further, close to 300 therapies targeting oncological disorders are in the early (pre-clinical and discovery phase) stages of development. CAR T cell therapy companies are developing therapies against several novel targets. Currently, over 210 CAR T cell therapy companies are involved in developing potential treatment options for oncological, non-oncological and other disorders. Additionally, players such as CARgen Therapeutics and Kite Pharma (a Gilead Sciences company) are revolutionizing CAR-T therapies manufacturing, driving impactful advancements in healthcare. Over 10,000 patents related to CAR T cell therapies have been recently filed / granted, demonstrating the continued innovation in CAR T cell therapy market. More than 260 partnerships and collaborations have been inked between several industry / academic stakeholders in order to expedite the development of various pipeline candidates. To fund CAR-T cell therapy development, capital investments worth more than USD 32 billion have been made by various private and public sector investors, in the last few years. According to the cancer data published by the Leukemia and Lymphoma Society in 2023, there were 59,610 new cases of leukemia, along with 89,380 new cases of lymphoma in the US. Based on the regional distribution, North America held 67% market share in 2024 (in terms of revenues generated through sales of approved CAR T cell therapies). Although the process of approval of CAR-T therapies is accelerated through various grants, the high prices of treatment options continue to be one of the key challenges associated with CAR T cell therapy adoption. Competitive Landscape of CAR-T Cell Therapy Market CAR-T cell therapy is among the most promising domains in the healthcare industry. Currently, over 210 CAR T cell therapy companies are involved in developing potential treatment options for oncological, non-oncological and other disorders. Additionally, players such as CARgen Therapeutics and Kite Pharma (a Gilead Sciences company) are revolutionizing CAR-T therapies manufacturing, driving impactful advancements in healthcare. In January 2024, Kite Pharma achieves a milestone with the FDA's approval of their advancement in manufacturing process for axicabtagene ciloleucel (Yescarta®), significantly eliminating the median turnaround time. CAR-T Cell Therapy Market Regional Outlook Based on the regional distribution, North America held more than 65% market share in 2024 (in terms of revenues generated through sales of approved CAR T cell therapies). Although the process of approval of CAR-T therapies is accelerated through various grants, the high prices of treatment options continue to be one of the key challenges associated with CAR T cell therapy adoption. By 2035, Asia Pacific is likely to capture more than 24% share of the global market share. However, in 2024 Yescarta (Axicabtagene Ciloleucel) became the first CAR T cell therapy to receive approval from NICE to be provided to the patients through NHS. As such, the Asia Pacific market will continue to grow at a healthy CAGR during the forecast period. CAR-T Cell Therapy Market Key Players The CAR-t cell therapy market report also includes detailed profiles of key players (listed below) that develops CAR-T cell therapies: Autolus bluebird bio Bristol Myers Squibb CARsgen Therapeutics Cellectis Gilead Sciences Innovative Cellular Therapeutics Noile-Immune Biotech Novartis Sinobioway Cell Therapy Takara Bio Wellington Zhaotai Therapies CAR-T Cell Therapy Market Segments Based on the research, Roots Analysis has segmented the CAR-T cell therapy Market into Type of Target Antigen, Type of Target Indication, Key Geographical Regions, Sales Forecast of CAR-T cell Therapies and Leading Players. CAR-T Cell Therapy Market, by Type of Target Antigen CD 19 B-cell Maturation Antigen (BCMA) CD 20 CD 19/22 Other Target Antigens CAR-T Cell Therapy Market, by Type of Target Indication Acute Lymphoblastic Leukemia Diffuse Large B-cell Lymphoma Follicular Lymphoma Large B-cell Lymphoma Mantle Cell Lymphoma Multiple Myeloma Others CAR-T Cell Therapy Market, by Key Geographical Regions North America Europe Asia Pacific Latin America Middle East and North Africa Rest of the World CAR-T Cell Therapy Market, Sales Forecast Approved Therapies Clinical Stage Therapies (Phase II and above) CAR-T Cell Therapy Market, by Leading Players Gilead Sciences Bristol Myers Squibb Novartis Janssen JW Therapeutics Browse Full Report Description + Research Methodology + Table of Content + Infographics here: https://www.rootsanalysis.com/reports/car-t-cell-therapy-market/269.html About Roots Analysis Roots Analysis is a global research and consulting powerhouse specializing in Healthcare, Pharmaceutical, Biotech, Semiconductors, Chemicals and ICT industry. With over a decade of experience, they’ve supported more than 750 clients — spanning Fortune 500 companies, innovative startups, academic institutions, VCs, and strategic investors. Why Use Roots Analysis in era of Artificial Intelligence? Tailored Insights Robust Methodology Smart Decisions Made Easy By combining world-class domain expertise, careful data gathering, and dialogue with senior industry experts, Roots Analysis ensures their deliveries are trustworthy, actionable, and aligned with strategic priorities. The value proposition generated on insights generated by Roots Analysis team is unparalleled in the market research industry. Services Offered: Consulting Services (custom insights supporting strategic and tactical requirements, off-the-shelf ready to consume work) Roots Analysis offers bespoke consulting services tailored to the unique needs of clients in the life sciences and healthcare sectors. They specialize in market assessments, tracking industry trends, dynamics, and competitive positioning. These insights help companies fine-tune their product strategies and market-entry plans. Roots Analysis also delivers expert guidance on partnerships, licensing, and investment opportunities. Their strategic support extends to KOL identification, publication analysis, and regulatory intelligence, making them a valuable partner in business growth and innovation. Subscription Services (bundled services supporting multiple topics and domains for a firm) With their subscription plans, Roots Analysis provides seamless access to a vast library of market intelligence reports. Subscribers enjoy unlimited downloads in multiple formats. The service includes on-demand research support—allowing clients to request tailored insights and initiate custom research topics. This ensures that emerging needs are met quickly and effectively. Each subscription comes with a dedicated account manager and direct access to analysts. Flexible billing options and tiered plans make this service suitable for organizations of all sizes seeking continuous, reliable insights. Contact Details for Roots Analysis Chief Executive: Gaurav Chaudhary Email: [email protected] Website: https://www.rootsanalysis.com/

View Less

Global CAR-T Cell Therapy Market Size & Industry Report

www.rootsanalysis.com

Global breast implants market size is expected to grow from USD 4.6 bn in 2024 to USD 5.1 bn in 2025 and USD 15.2 bn by 2035, at CAGR of 11.4%

harnoor baidwan

Link